Aims: We aimed to examine the changes in plasma pentosidine and serum 8-hydroxy-2’-deoxyguanosine (8-OHdG) levels in patients with end-stage renal disease (ESRD) undergoing light-shielding hemodialysis.\nMethods: Light-shielding hemodialysis, in which the blood circuits and dialyzer are wrapped in aluminum foil, was administered to 10 ESRD patients who underwent 12 sessions over four weeks. Baseline plasma pentosidine levels were measured under ordinary hemodialysis, and then after four and 12 sessions of light-shielding hemodialysis. Serum 8-OHdG levels were measured before and after the 12 sessions of light-shielding hemodialysis. \nResults: Pentosidine levels were decreased under light-shielding hemodialysis in 6/10 patients. Overall, pentosidine levels after four sessions (0.610 ± 0.216 μg/mL) and 12 sessions (0.589 ± 0.188 μg/mL) of light-shielding hemodialysis were significantly lower than baseline (0.751 ± 0.286 μg/mL). The 8-OHdG levels after 12 sessions of light-shielding hemodialysis (0.90 ± 0.17 ng/mL) were significantly lower than baseline (1.02 ± 0.22 ng/mL).\nConclusion: Our study indicated that light-shielding hemodialysis may be an effective treatment for reducing serum levels of advanced glycation end products in some patients with ESRD undergoing hemodialysis.

Login to Download PDF

Please login with your Paper ID and password to access the full PDF.

🔑 Login to Download